PROSPECT provides clinicians with supporting arguments for and against the use of various interventions in postoperative pain based on published evidence and expert opinion. Clinicians must make judgements based upon the clinical circumstances and local regulations. At all times, local prescribing information for the drugs referred to must be consulted.
Laparoscopic resection has become the standard surgical technique for treatment of colorectal cancer, associated with less postoperative pain and shorter hospital stays than open surgical techniques (Millo 2013).
The aim of the current review (Lirk 2023) was to evaluate the current literature on postoperative pain management following laparoscopic colorectal surgery and update the previous procedure-specific pain management recommendations (Joshi 2012).
The unique PROSPECT methodology is available at https://esraeurope.org/prospect-methodology/. The PROSPECT Working Group considered study quality, clinical relevance of trial design (including critical evaluation of the baseline pain treatment), and a comprehensive risk-benefit assessment of each analgesic intervention to determine its relevance in current peri-operative care.
Literature databases were searched up to January 2022, taking into account the previously published guidelines (Joshi 2012).
COX, cyclooxygenase; NSAID, non-steroidal anti-inflammatory drug.
Interventions that are not recommended for pain management in patients undergoing laparoscopic colorectal surgery.
PROSPECT recommendations for laparoscopic colorectal surgery – infographic
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.